SLS stock jumped 156% on the Phase 3 result its loudest bears said would fail

By Maya Koeva · November 18, 2026 · 7 min read

CompanySELLAS Life Sciences Group, NASDAQ: SLS, a clinical-stage biotech
DrugGalinpepimut-S (GPS), an immunotherapy for acute myeloid leukemia (AML)
REGAL result126 patients, hazard ratio 0.59, p=0.035, median survival 24.0 vs 14.7 months
SLS close$19.15 on November 17, 2026, up from $7.47 the day before
Pre-data closing high$15.46 on August 21, 2026
Next stepSellas plans to file for FDA approval in the first half of 2027
7-day score54 (Weak) on the morning of November 18, 2026

A short amber chain of linked circles, shaped like a key, fitting a notch in a large outlined circle among smaller circles and one blue dot, on a dark background

SLS stock: what Sellas reported on November 17

Before the market opened on November 17, Sellas said REGAL, its Phase 3 trial of galinpepimut-S in AML patients in second remission who can't get a stem cell transplant, met its primary endpoint of overall survival. The numbers, from the company's press release filed with the SEC:

  • 126 patients, randomized 1:1 to GPS or the investigator's choice of best available treatment.
  • Hazard ratio 0.59, which Sellas reports as a 41% reduction in the risk of death.
  • Two-sided p=0.035.
  • Median overall survival of 24.0 months on GPS against 14.7 months on standard treatment.

Sellas plans to meet the FDA about an accelerated filing and to submit a Biologics License Application in the first half of 2027. The drug is not approved anywhere yet.

(If you searched "SLS stock" for NASA's Space Launch System rocket, it has no ticker. This page is about Sellas.)

SLS stock price: from the June run to $19.15

DateSLS closeWhat happened
June 29$15.45June run, the busiest SLS day in our feeds
August 21$15.46Closing high before the data
September 17$11.53Feuerstein: the study "will end in failure"
October 28$10.3880th death reached; 14.7% on the day
November 16$7.47Last close before the data, 51.7% under the August high
November 17$19.15156.4% on the REGAL result

The trial was event-driven: the final analysis ran once 80 patients had died. Sellas announced the 80th event on October 28. In 2022 Sellas had expected that milestone by the end of 2024. SLS fell 14.7% that day and kept falling for three more sessions.

The November 17 move was bigger before the open. Posts in the app's feed put premarket trades between about $26 and $33, and one r/wallstreetbets poster sold at $27.25. Within minutes another asked whether the stock had lost "like 100% in gains in like 10 minutes," and posters in the same thread described a trading halt. SLS closed at $19.15, its highest close in the past year.

Price
$19.15+125% over the window+156% off the low
Jun 22Nov 17
SLS daily closes, June 22 to November 17, 2026: the June run to $15.45, the August high of $15.46, the slide to $7.47 on November 16 and the $19.15 close on the REGAL result.

The bears: Adam Feuerstein and Martin Shkreli

Two well-known biotech skeptics spent months saying REGAL would fail. Both post on X, where Quantral follows them.

Adam Feuerstein, the STAT News biotech columnist, wrote on September 17 that the long-delayed study "will end in failure" and linked his STAT column. On October 28, after the 80th event, he suggested his followers compile "a list of all the ways" the CEO would "spin the failure." On the morning of November 17 he posted: "It looks like I was wrong about Sellas Life Sciences."

Martin Shkreli told a follower in early March he was "very bearish, it will fail," Stocktwits reported. In August he hosted calls with AML specialists about the stock. On November 17 he stuck to his view: p=0.035 "means 1 patient tipping point to p>0.05," he posted, and he shared a video on Nvidia's earnings and the trial under the line "SLS data is sketch."

The receipts, by price from the day of each call to the November 17 close:

AccountCallDateSLS closeSince
@MartinShkreli"Very bearish, it will fail"March 9 (as reported)$5.96221.3%
@adamfeuerstein"Will end in failure"September 17$11.5366.1%
@adamfeuerstein"Spin the failure"October 28$10.3884.5%

Shkreli's November 17 posts came while SLS traded far above where it closed, so the day's fade went his way, though the trial result went against him. Quantral logged his two November 17 posts as one open call: SLS down, over 30 days from the $19.15 close. The app grades it on December 17.

SLS stock on Reddit: r/wallstreetbets held through a 52% slide

From June 1 to November 17, the accounts we track posted about SLS 275 times, and 251 of those came from r/wallstreetbets. The subreddit ran 156 bullish to 51 bearish. The X accounts we follow leaned the other way, 14 bearish to 9 bullish.

MonthMentionsBull : BearMonth-end close
June12772 : 31$14.76
July3119 : 9$10.01
August7146 : 14$13.34
September52 : 3$12.31
October149 : 4$9.68
November (to the 17th)2717 : 4$19.15
Mentions
304
80
77
Jun 1Aug 24Nov 17
Weekly totals
PositiveNegativeChatterNoise
SLS mentions across the accounts Quantral tracks, June 1 to November 17, 2026, in weekly totals: the late-June run, the August posts, a quiet autumn and the November 17 result.

The June run brought the crowd in. On June 29, the busiest day, SLS drew 49 mentions, 32 of them bullish, as posters pointed to short interest near 34% and argued for a squeeze before any data.

The stock slid from there. In late July one poster wrote that they were down $700,000 since June 29. By mid-October, with the stock around $11, the jokes had turned on the trial itself: "The trial will never end. SLS will remain $11-12 forever." In the same thread another poster said their whole net worth was in the stock.

The holders with diamond hands got paid on November 17. One poster who bought near $8 the week before put it this way: "sometimes you idiots are right."

What the trial data does and does not settle

Shkreli's objection is a real statistical point. A p-value of 0.035 clears the usual 0.05 bar, but not by much in a 126-patient trial. Other questions the release leaves open:

  • No confidence interval. The topline release gave the hazard ratio without one, as Tech Times noted.
  • The finish line moved. In November 2022 Sellas cut the final analysis to 80 deaths from 105, after pooled blinded data showed longer survival than planned.
  • Open-label design. Patients and doctors knew which treatment each patient got.
  • Approval is a separate step. The FDA has not reviewed the full data, and the filing is planned for 2027.

One readout like this is the binary risk that comes with small biotech stocks. No account in the SLS feed had the data before November 17, and Quantral didn't either. The app shows who said what and when, and it grades every call it tracks, losers included.

What to take from this

The SLS argument ran for five months across two very different rooms. On X, two famous skeptics called the trial a failure. On r/wallstreetbets, holders kept posting through a 52% slide. The data came out on the bulls' side, and SLS now trades 66% to 221% above where it closed on the days of the bears' calls. Quantral kept every one of those posts in the SLS feed with the account behind it, so before the next readout you can check who has been right. On the morning of November 18, SLS scored 54 (Weak) on 7 days. Over the three months to November 17, its median daily move was 3.4%, and November 17 alone was 156%.

Daily moves
3.4%
median daily move
Biggest day
+156.4%
+160%0%−15%
+156%
Aug 19Nov 17
SLS daily close-to-close moves, August 19 to November 17, 2026, on one scale.
Download on the App StoreGet it on Google Play

SLS stock FAQ

Why did SLS stock go up?

SELLAS Life Sciences said on November 17, 2026, that its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia met its primary endpoint, with a hazard ratio of 0.59 for death and a two-sided p-value of 0.035. SLS closed at $19.15, up 156.4% from $7.47.

What is the SLS stock forecast?

Quantral doesn't publish price targets. It reports what the accounts it tracks say and grades their calls. From June 1 to November 17 those posts ran 165 bullish to 65 bearish, most of them on r/wallstreetbets. The next company milestone is an FDA filing planned for the first half of 2027.

What is the SLS stock price?

SLS closed at $19.15 on November 17, 2026. Its previous closing high was $15.46 on August 21, 2026.

What does Reddit say about SLS stock?

r/wallstreetbets was the loudest room on SLS in the accounts we track, with 251 of 275 mentions from June 1 to November 17, 156 bullish and 51 bearish. Posters held through the slide from the August high and posted gains after the November 17 result.

Did Adam Feuerstein say SLS would fail?

Yes. He wrote on September 17, 2026, that the study "will end in failure" and repeated the call on October 28. On November 17 he posted that it looked like he was wrong.


Trial figures come from the SELLAS press release filed with the SEC on November 17, 2026. Other facts come from the reports linked above. SLS prices are daily closes through November 17, 2026. Mentions and quoted posts come from the accounts Quantral tracks, by US Eastern day; Reddit posters are quoted without usernames. The 7-day score is as of the morning of November 18, 2026. Quantral surfaces signals and context from public sources to support your own research. Nothing here is financial advice or a recommendation to buy or sell. Past signals are not indicative of future results.